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Cocrystal Structures of Diaminopimelate
Decarboxylase: Mechanism, Evolution, and Inhibition
of an Antibiotic Resistance Accessory Factor
tance is a low-affinity penicillin binding protein, PBP2a
[9, 10, 11], encoded by the mecA gene [12]. It has been
known for some time, however, that the presence of the
mecA gene and its protein product cannot fully account
for resistance in clinical isolates of MRSA, which demon-
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(MICs) across isolates bearing comparable levels of3 Howard Hughes Medical Institute
The Rockefeller University PBP2a [13, 14]. Genetic analysis of transposon mutants
of MRSA identified a number of auxiliary genes that work1230 York Avenue
New York, New York 10021 in synergy with PBP2a and appear to be essential for
high-level methicillin resistance in S. aureus. Several of
these auxiliary genes encode enzymes involved in cell
wall metabolism, while the biochemical and cellular
functions of other auxiliary resistance gene productsSummary
remain unknown [15]. One of these auxiliary genes,
aux239, was identified on the basis of DNA sequenceCocrystal structures of Methanococcus jannaschii di-
aminopimelate decarboxylase (DAPDC) bound to a homology as the S. aureus gene encoding diaminopi-
melate decarboxylase (DAPDC) [16].substrate analog, azelaic acid, and its L-lysine product
have been determined at 2.6 A˚ and 2.0 A˚, respectively. In bacteria, L-lysine is derived from L-aspartate via a
multistep biosynthetic pathway, with three slightly dif-This PLP-dependent enzyme is responsible for the fi-
nal step of L-lysine biosynthesis in bacteria and plays ferent intermediate pathways that operate in parallel and
converge to give daminopimelate, or DAP (Figure 1A).a role in-lactam antibiotic resistance in Staphylococ-
cus aureus. Substrate specificity derives from recog- DAPDC catalyzes the final common decarboxylation
step to yield the end product L-lysine [17]. Unlike bacte-nition of the L-chiral center of diaminopimelate and a
system of ionic “molecular rulers” that dictate sub- ria, humans obtain L-lysine from dietary sources and
lack the biosynthetic machinery depicted in Figure 1A;strate length. A coupled-enzyme assay system permit-
ted measurement of kinetic parameters for recombi- the closest human ortholog of S. aureus DAPDC (Sa-
DAPDC) is ornithine decarboxylase (ODC; sequencenant DAPDCs and inhibition constants (Ki) for azelaic
acid (89M) and other substrate analogs. Implications identity, 25%).
In many bacteria, including S. aureus, lysine is thefor rational design of broad-spectrum antimicrobial
agents targeted against DAPDCs of drug-resistant essential diamino acid component of the bacterial cell
wall peptidoglycan, the structural stability of which criti-strains of bacterial pathogens, such as Staphylococ-
cus aureus, are discussed. cally depends on peptide crosslinks formed between
the N6 amino group of lysine and the carboxyl function of
D-alanine residues in neighboring muropeptide subunitsIntroduction
of the cell wall. The inhibitory power of methicillin and
other -lactam antibiotics derives from blockage of pep-Antibiotic resistance in pathogenic bacteria has become
a major public health concern [1]. High-level utilization tide crosslink formation, via inhibition of the transpepti-
dase functions of penicillin binding proteins (PBPs).of -lactams and other antimicrobial agents have placed
the bacterial ecosystem under tremendous selection Loss of peptide crosslinks compromises the integrity of
the cell wall, leading to bacterial death.pressure, leading to the emergence of multidrug-resis-
tant strains of major human pathogens, such as Staphy- A transposon insertion into the gene encoding DAPDC
of the MRSA strain COL did not affect growth in richlococcus aureus [2]. By early 1990 epidemic clones of
methicillin-resistant Staphylococcus aureus (MRSA) organic media but reduced the level of methicillin resis-
tance by nearly 100-fold [16]. Supraphysiologic concen-had been detected around the world [3, 4], and strains
that remain susceptible to only one therapeutically use- trations of L-lysine (e.g., 10 mM) partially overcame the
observed loss of methicillin resistance. DAPDC, there-ful antimicrobial agent, vancomycin, have been de-
scribed [5]. Since 1997 sporadic isolates of MRSA with fore, represents a potential target for broad-spectrum
inhibitors, either for use as primary antibiotics or asreduced susceptibility to vancomycin have also been
reported in several countries [6, 7, 8]. These develop- adjuncts to existing therapies.
Extensive attempts to obtain diffraction-quality crys-ments raised the specter of untreatable staphylococcal
disease [1], stimulating a systematic search for new tals for DAPDC from S. aureus failed. An ortholog iso-
lated from Methanocococcus jannaschii (sequenceantimicrobial agents against MRSA and substantial re-
search efforts focused on mechanisms of drug resis- identity to S. aureus enzyme, 38%) proved more amena-
ble to crystallization. Here, we present X-ray structurestance in MRSA.
In MRSA the primary determinant of antibiotic resis- of M. jannaschii DAPDC (Mj-DAPDC) bound to a sub-
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Figure 1. L-Lysine Biosynthetic Pathways and DAPDC Inhibitors
(A) Schematic representation of L-lysine biosynthesis pathways in bacteria.
(B) Chemical structures and Ki values (where appropriate) for substrate, product, and structurally similar inhibitors.
strate analog, azelaic acid, and its product, L-lysine. structural motif of the / barrel domain is an  helix.
Modeling of DAP in the active site permitted elucidation The largely C-terminal  sandwich domain contains an
of the mechanism of substrate recognition. A coupled-  helix and a  strand derived from the N terminus
enzyme assay was used to examine the inhibitory prop- of the protein, which makes extensive intramolecular
erties of azelaic acid with DAPDCs from M. jannaschii, contacts with a C-terminal “Greek key” motif. The en-
S. aureus, and Escherichia coli. Implications for rational zyme forms a symmetric homodimer in the crystal with
design of DAPDC inhibitors are discussed. an extensive intersubunit interface (Figure 2A). Both the
N- and C-terminal domains participate in dimer forma-
tion. In addition, the C terminus of one monomer isResults and Discussion
draped across its partner, further stabilizing the homodi-
mer. As expected, two PLP molecules (one per mono-Structural Overview
mer) were seen in the electron density map, identifyingM. jannaschii DAPDC is a 50 kDa two-domain enzyme
the location of the two active sites within the dimerwith atypical 8-fold / barrel and  sandwich domains
interface (Figure 2A). The PLP moiety makes a Schiff’s(Figure 2A). DAPDC belongs to the type III class of di-
base with Lys73, a feature observed frequently in othermeric PLP enzymes (alanine racemase family). Unlike
classical TIM barrel enzymes, the N-terminal secondary members of this class of PLP-dependent enzymes, such
Crystal Structure of Diaminopimelate Decarboxylase
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Figure 2. Structure of the Mj-DAPDC/Azelaic
Acid Complex
(A) Ribbon diagram of the Mj-DAPDC homo-
dimer with PLP cofactor and bound azelaic
acid inhibitor depicted as color-coded space-
filled atoms (C, gray; N, blue; O, red; P, yel-
low). One of the monomers is uniformly col-
ored red. The second monomer is colored
to show the TIM barrel (blue), the N-terminal
portion of the  sandwich domain (yellow),
and the C-terminal part of the  sandwich
domain (green).
(B and C) Active site electron density features
(|Fobserved|  |Fcalculated| difference Fourier syn-
thesis contoured at 1 , corresponding to
bound (B) azelaic acid, depicted as a color-
coded atomic stick figure in two possible
conformations, and (C) L-lysine.
as ornithine decarboxylase [18]. Bound azelaic acid ap- tern of amino acid differences across archaea and eu-
bacteria allow us to conclude that all known DAPDCspears to exist in multiple conformations, as judged from
the electron density map illustrated in Figure 2B. share the same three-dimensional structure [19]. Sur-
face electrostatic potential calculations demonstrate the
presence of a conserved, highly basic surface featureDAPDC Sequence Comparison
within the enzyme active site, which is consistent withFigure 3A documents that about 25% of the 434 residues
recognition of carboxylate groups in the substrate andcomposing Mj-DAPDC are highly conserved among the
Couloumb repulsion of the positively charged L-lysinemembers of this PLP enzyme subfamily. Without excep-
product (Figures 3B and 3C).tion, all sites at which there are significant differences
map to the surface of the enzyme (Figure 3B), where
mutations would be readily tolerated, or represent con- DAPDC Active Site and Substrate Recognition
The active site of DAPDC is composed of residuesservative changes of buried residues unlikely to destabi-
lize the hydrophobic core. Insertions and deletions in from both dimer subunits (Lys73A, His214A, Arg297A,
Tyr337A, Cys362B, Glu363B, and Ser364B; A and B de-the DAPDC sequences, aligned in Figure 3A, map to
random coil portions of the structure, where they would note individual protomers). Figure 4A depicts the azelaic
acid-bound enzyme active site in detail. Each PLP formsnot disrupt organized secondary-structural elements.
The remarkable level of sequence identity and the pat- a Schiff’s base with Lys73A and stacks with His214A or
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Figure 3. DAPDC Sequence Alignment and
Surface Properties
(A) Sequence alignment of DAPDCs from se-
lected pathogens. Secondary-structural ele-
ments are shown with cylinders ( helices)
and arrows ( strands). Gray dots denote
poorly resolved residues in the final electron
density map. Color-coding denotes sequence
conservation among DAPDCs (white to green
ramp, 30%–100% identity). Red asterisks de-
note invariant or near-invariant active site res-
idues.
(B) GRASP [42] representation of the chemi-
cal properties for the solvent-accessible sur-
face of Mj-DAPDC, calculated with a water
probe radius of 1.4 A˚. Solvent-accessible sur-
face color-coded for (left panel) sequence
conservation with the color ramp in (A) and
(right panel) the calculated electrostatic po-
tential (red and blue, respectively, represent
electrostatic potentials 8 and 8 KBT,
respectively, where KB is the Boltzmann con-
stant and T is the temperature). The calcula-
tions were performed with an ionic strength
of zero and dielectric constants of 80 and
2 for solvent and protein, respectively. The
active site (invariant and highly basic) and the
dimer interface (conserved) are labeled.
the corresponding residues in subunit B. Arg297A constraint requires recognition of at least one, if not
both, stereochemically distinct centers within the sub-makes a salt bridge with the carboxylate group of azelaic
acid remote from the PLP cofactor. Other interactions strate. In an attempt to understand substrate recognition
by Mj-DAPDC, we modeled DAP into the active site inbetween the enzyme and azelaic acid include the follow-
ing: His214A, NE2 → O1  3.6 A˚; Arg297A, closest con- place of azelaic acid (Figure 4B). The L-stereocenter
of the modeled substrate could be recognized by thetact, NH2 → O8  2.7 A˚; Tyr337A, OH-O9  3.3 A˚;
Ser364B, N → O1  3.7 A˚ (Table 1; see Figure 4A for enzyme via interactions analogous to those seen with
azelaic acid, with the location of the D-stereocenter be-the azelaic acid atom-numbering scheme). Between the
salt bridges, the aliphatic backbone of azelaic acid ex- ing dictated by the formation of a Schiff’s base with
PLP. Following adjustment of the torsion angles of twohibits conformational flexibility. Similar behavior is often
observed when NZ atoms of lysine side chains make active site residues (Arg297A and Glu363B; Figure 4B),
the modeled substrate could form salt bridges and hy-salt bridges or hydrogen bonds [20].
Diaminopimelate is a meso compound with opposite drogen bonds with residues from both halves of the
dimer (Figure 4B). Recognition of the L-stereocenter ap-chiralities at each terminus (referred to as “D-stereocen-
ter” and “L-stereocenter,” hereafter). Productive decar- pears to result from two salt bridges: Glu363B and
Arg297A with the substrate amino (L-stereocenter) andboxylation must occur at the D-stereocenter to ensure
synthesis of L-lysine and not D-lysine. This mechanistic carboxylate (L-stereocenter) groups, respectively. In ad-
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with the L-stereocenter making the Schiff’s base) failed
because of severe steric clashes (data not shown).
Inspection of DAPDC sequences from various organ-
isms demonstrates absolute conservation of all active
site residues observed in azelaic acid binding and those
implicated in substrate binding in our model of the en-
zyme-substrate complex (Figure 3A, asterisk), with only
one exception, Ser364B (serine or threonine in all avail-
able DAPDC sequences). We believe that the proposed
model for substrate recognition is common to all known
DAPDCs.
Evolution of Type III PLP Enzymes: “Made
to Measure” Active Sites
Both DAPDC and its ortholog, ODC, are members of
the alanine racemase (AR), or type III, family of PLP-
dependent enzymes. Figure 5A illustrates a superposi-
tion of AR (orange), ODC (blue), and Mj-DAPDC (green)
prepared by overlaying the / barrel domains (rmsd ca.
1.9 A˚ for230 equivalentcarbons). The only significant
structural differences between these three enzymes re-
sult from modest rotations of the  sandwich domains
with respect to the / barrels.
In terms of both size and chemical complexity, alanine
is the simplest of the three enzyme substrates in ques-
tion. The cocrystal structure of AR bound to ethylamine
phosphonate shows that the phosphonate group (analo-
gous to the carboxylate group of alanine) makes a salt
bridge with Arg257B (bold text denotes AR residues;
Figure 5B). Cys311B of AR acts as the catalytic residue
to effect the racemization reaction [21]. L-ornithine and
Figure 4. DAPDC Active Site DAP represent somewhat more complicated, yet chemi-
(A) Ribbon representation of the two polypeptide chains comprising cally similar, substrates. When the active sites of ODC
the dimeric enzyme, with monomers A and B colored gold and blue, and DAPDC are overlayed, the two enzymes display
respectively. Active site residues and azelaic acid are depicted as similar spatial dispositions of active site residues (Figure
color-coded atomic stick figures (N, blue; C, gray; O, red; S, yellow;
5B). His214A in Mj-DAPDC and His197A in ODC (italicP, orange) with a shaded molecular surface representation empha-
text denotes ODC residues) occupy structurally equiva-sizing polar atoms (gray, C; red, O; blue, N). Lys64A has been omitted
for the sake of clarity. The carbon atoms of the inhibitor backbone lent positions, making 	-	 stacking interactions with
have been numbered. their respective PLP cofactors. On the basis of a detailed
(B) Atomic stick figure representation of DAP modeled in the active structural comparison, Cys360B, the catalytic residue
site to permit formation of the required Schiff’s base with PLP and in ODC [18], corresponds to Cys362B in Mj-DAPDC,
to optimize ionic interactions with the L- and D-stereocenters that
suggesting that the catalytic mechanisms of these twoare analogous to the observed contacts with azelaic acid. Color-
enzymes are probably identical (Figure 5B).coding is as in (A), with intermolecular distances given for atoms at
the L-stereocenter. The substrates of these closely related enzymes are,
however, chemically distinct, and there is no substrate
crossreactivity between ODC and DAPDC [22]. Asp361B
in ODC makes a salt bridge with the  amino groupdition to the Schiff’s base between the amino group of
the D-stereocenter of DAP and PLP, the carboxylate of L-ornithine. The equivalent position in Mj-DAPDC is
occupied by Glu363B, which could make an analogousgroup at the D-stereocenter of the substrate could make
hydrogen bonds with His214A and Ser364B. Attempts salt bridge with the L-stereocenter of DAP. This subtle
difference almost certainly reflects the fact that L-orni-to model the substrate in the opposite orientation (i.e.,
Table 1. Distances between Atoms of Amino Acid of DAPDC and Ligands
M. jannaschii DAPDC Azelaic Acid (2.6 A˚ resolution) L-Lysine (2.0 A˚ resolution)
PLP C4 → O1  3.6 A˚ C4 → NZ  3.4 A˚
His214A NE2 → O1  3.7 A˚ NE2 → NZ  5.2 A˚
Arg297A NH2 → O8  2.7 A˚ O → NH2  3.4A˚
Try337A OH → O9  3.3 A˚ OH → N  4.3 A˚
Cys362B SG → O1  6.6 A˚ SG → NZ  3.4 A˚
Glu363B OE2 → C5  3.5 A˚ OE2 → N  4.2 A˚
Ser364B N → O1  3.7 A˚ O → NZ  4.2 A˚
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Figure 5. Comparison of AR, ODC, and DAPDC
(A) Ribbon drawing superposition of AR (orange), ODC (blue), and Mj-DAPDC (green).
(B) Comparison of the active sites of AR, ODC, and DAPDC. Arg257B in AR, Asp361B and Asp332A in ODC, and Glu363B, Tyr337A, and
Arg297A in DAPDC act as molecular rulers contributing to recognition of their respective substrates. (Inset) Superposition of the active site
residues of Mj-DAPDC and ODC, showing the correlation between the lengths of the substrates and the acidic residues responsible for salt
bridge formation between substrate and enzyme.
thine is one carbon-carbon bond-length shorter than PLP-dependent enzymes are probably similar. In the
first essential step, all three enzymes make a Schiff’sthe DAPDC substrate. We believe that these enzymes
use Asp361B/Glu363B as “molecular rulers” to “mea- base adduct with the substrate amino group. However,
the substrates for the three enzymes differ in their chem-sure” the lengths of substrates bound in their respective
active sites (Figure 5B). The presence of Ser364B in Mj- ical complexity, particularly at the nonreactive ends of
the substrate. AR is the simplest of the three and re-DAPDC, which is analogous to Gly362B in ODC, can be
explained, at least in part, by the requirement for DAPDC quires only one molecular ruler, Arg 257B, to recognize
the carboxylate group of either D- or L-alanine. ODCto recognize the D-stereocenter of its meso substrate.
ODC has no such constraint because its natural sub- appears to utilize at least two molecular rulers (Asp332A
and Asp361B) to form salt bridges with the 
 aminostrate exists only in the L configuration.
The catalytic mechanisms of each of these type III group of L-ornithine, without undesired binding to the
Crystal Structure of Diaminopimelate Decarboxylase
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 amino group of its closest chemical analog, L-lysine. be too bulky to fit into the enzyme active site. Suberic
acid and 2,4-pentenedioic acid are very similar to azelaicThe active sites of DAPDCs recognize a substrate of
even higher complexity and must also discriminate be- acid, except that these dicarboxylic acids are unsatu-
rated. Surprisingly, these compounds appear to havetween the two chiral centers of DAP. Mj-DAPDC and,
by inference, all DAPDCs appear to do so with three almost no inhibitory effect. It is possible that torsion
angle flexibility of the fully saturated aliphatic substratemolecular rulers (Arg297A, Tyr337A, and Glu363B in Mj-
DAPDC). We suggest that AR, ODC, and DAPDC have analogs contributes to inhibitor binding because azelaic
acid can be modeled in at least two conformations (Fig-evolved increasingly complex active sites, which reflect
the increasing chemical complexity of their respective ure 2B). The rigid double bonds in suberic acid and 2,4-
pentenedioic acid would not permit the same torsionalsubstrates. It also appears likely that the precise way
in which the DAPDCs recognize DAP favors decarboxyl- flexibility and could thereby increase the entropic pen-
alty of active site binding. This phenomenon has beenation over the other types of chemical reactions, such as
transaminations and racemization, commonly catalyzed previously seen for inhibitors of HIV protease [25].
Diamines appear to be much stronger DAPDC inhibi-by PLP-dependent enzymes [23].
tors than dicarboxylic acids. The addition of various
diamines to Mj-DAPDC leads to a slight decrease inStructure of the Mj-DAPDC/Product Complex
intensity of the UV absorption of PLP at 430 nm, sug-L-lysine (the product of DAP decarboxylation) is a known
gesting that these inhibitors make Schiff’s bases withfeedback inhibitor of the DAPDCs [24]. Determination
the enzyme cofactor. Moreover, ultrafiltration of the Mj-of the structure of Mj-DAPDC from crystals grown in
DAPDC/diamine complex through a porous membranethe presence of added L-lysine revealed an active site
(MW cutoff, 10 kDa) led to retention of the protein andelectron density feature that cannot be accounted for
passage of PLP (data not shown), indicating that theby the sequence of the protein, PLP, or water molecules.
colored cofactor had dissociated from the enzyme afterThis feature could be readily explained by the presence
diamine addition. The strong inhibitory effect of the di-of the bound product L-lysine (Figure 2C). There are no
amines may be attributed to PLP sequestration, whichmajor differences in the conformations of the active site
precludes recycling of the enzyme after inhibitor bind-residues in the structures of the monoclinic (L-lysine-
ing. The Ki for L-lysine, the end product feedback inhibi-bound) and hexagonal (azelaic acid-bound) crystal
tor of DAPDC, could not be measured. We believe thatforms of Mj-DAPDC, except for the side chain of
the Ki for L-lysine falls outside the range of detectionCys362B, which points in a different direction (Table 1).
by our coupled-enzyme assay system, implying a lowerIf, indeed, the electron density feature adjacent to the
limit of about 500–1000 M.PLP cofactor does correspond to bound product, the
conformation of Cys362B is consistent with the catalytic
mechanism of ODC. The sulfhydryl group of Cys362B Biological Implications
lies closest to the  carbon of the bound L-lysine prod-
uct, where it can carry out the final catalytic step by a DAPDC has a number of features that make it an attrac-
mechanism similar to that of ODC [18]. tive drug design target. First, this enzyme is found only
in bacteria, and humans obtain the amino acid L-lysine
from dietary sources. Second, DAPDC catalyzes the fi-Enzymatic Activity and Inhibition of DAPDC
Mj-DAPDC follows simple Michaelis-Menten’s kinetics, nal step common to all known L-lysine biosynthesis
pathways in prokaryotes. Third, the active sites of thewith no apparent cooperativity between subunits (data
not shown). The specific activity of the purified enzyme M. jannaschii and S. aureus enzymes appear to be identi-
cal in structure, and there is good reason to believe thatpreparation used for crystallography was 2.7 0.4 units/
mg, and the Km is 588  12 M. Comparable specific DAPDC inhibitors will have a broad spectrum of action.
Finally, it has been demonstrated that inactivation ofactivities were obtained for purified, recombinant Ec-
DAPDC and Sa-DAPDC (3.8  0.2 units/mg and 3.3  the gene encoding DAPDC of S. aureus causes a 100-
fold reduction in the MIC for methicillin [16].0.3 units/mg, respectively). Azelaic acid was tested for
its potential to inhibit the M. jannaschii enzyme and From a mechanistic standpoint, DAPDC occupies a
unique position among amino acid biosynthesis en-found to have a Ki of 89  15 M. Added substrate
reverses inhibition, demonstrating that azelaic acid is a zymes. Unlike other decarboxylases, DAPDC acts on a
meso substrate and is specific for the D-stereocenter.competitive inhibitor.
Ten other DAP-like compounds were tested for inhibi- Other D amino acid oxidases use FAD as a cofactor,
making cross inhibition of this class of enzymes bytion of Mj-DAPDC, and apparent Ki values are summa-
rized in Figure 1B. Together with azelaic acid, these DAPDC inhibitors unlikely. Orthologous human enzymes
responsible for decarboxylating amino acids (e.g., ly-compounds encompass much of the chemical complex-
ity of DAP. Caproic acid is a simple carboxylic acid that sine, ornithine, and histidine decarboxylases) act only
on L substrates. The substrate recognition propertiesbinds weakly to the enzyme. Adipic acid is a six carbon
dicarboxylic acid that is similar to azelaic acid. The ap- of DAPDC make it an appealing target for mechanism-
based drug design, because it is unlikely that an inhibitorparent Ki for adipic acid is slightly higher than that of
azelaic acid, which may be explained by unfavorable bearing a D-chiral center will interfere with metabolism
of other amino acids. The evolutionary understandingelectrostatic interactions with the carboxylate group of
Glu363B, limiting binding to DAPDC. The hydrazine de- gained from structural comparison of enzymes in this
family should allow design of stereoselective inhibitorsrivative of adipic acid has no significant effect and may
Structure
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Table 2. Summary of Crystallographic Statistics
Data Collection and Refinement
Azelaic acid Azelaic acid (Pt) L-lysineData set
Space group P6122 P6122 P21
Unit cell parameters a  80.8 A˚ a  80.9 A˚ a  70.2 A˚
c  508.5 A˚ c  508.6 A˚ b  147.1 A˚
c  89.4 A˚
  93.3
Wavelength   1.4 A˚   1.07 A˚   0.98 A˚
Protomers/AU 2 2 4
Number of measurements 257,466 98,834 654,629
Number of unique reflections 30,684 9,707 119,738
Resolution range 30–2.6 A˚ 20–3.7 A˚ 30–2.0 A˚
Completeness (%)a 96.0 (88.9) 83.5 (45.9) 99.1 (100)
Rmerge (%)a,b 7.0 (15.6) 9.4 (9.6) 3.5 (10.1)
Average intensity [I/(I)]a 32.8 (10.7) 30.9 (15.8) 35.4 (13.1)
Average multiplicity 8.4 10.2 5.5
Working R factor (%) 24.4 22.3
Free R factor (%) 28.3 25.9
Rms deviations
Bond lengths (A˚) 0.006 0.007
Bond angles () 1.48 1.99
Overall G factorc 0.2 0.0
Phasing Statistics
Number of heavy atom sites 7
Resolution range used for phasing 20–3.7 A˚
Phasing power (acentric)d 1.35
Mean figure of merit (FOM)e 0.48
Resolution range used for density modification 30–2.6 A˚
Mean FOM after density modification using NCS 0.74
Model Statistics
Number of atoms 6,955 14,871
Number of water molecules 91 13,80
Overall B factor 33 18
a Numbers in parentheses indicate statistics for the highest resolution shell.
b Rmerge  [hkl i|I(hkl)i  I(hkl)|/hkliI(hkl)i]  100, where I(hkl) denotes mean intensity.
c PROCHECK statistics [40].
d Phasing power  rms(FH/E), where E is the residual lack of closure.
e FOM  F(hkl)best/F(hkl), where F(hkl)best  aPFhkl/aP.
that target bacterial DAPDCs, with minimal crossinhibi- kill a pathogenic bacterium in vivo because the host
milieu supplements the missing reaction product(s). Al-tion of enzymes contributing to amino acid synthesis
and metabolism in humans. though we think it extremely unlikely for DAPDC, given
the high concentrations of L-lysine required to overcomeAlthough azelaic acid and the diamines bind Mj-
DAPDC with reasonable affinities, none of these highly loss of enzyme activity in vitro, this scenario remains a
formal possibility. Even in this context, an inhibitor ofpolar molecules (with attendant poor membrane perme-
ability) inactivate DAPDC in vivo (data not shown). We DAPDC may be of clinical utility in combination with a
-lactam antibiotic. In a widely used combination drug,suggest that -fluoromethyl analogs of DAP represent
credible lead compounds for the development of Augmentin, the inclusion of clavulanic acid inhibits
-lactamase, thereby allowing the antimicrobial compo-DAPDC inhibitors because the proposed flourine modifi-
cations would increase membrane permeability [26]. nent amoxycillin to reach its target. By analogy, inhibi-
tion of an auxiliary gene, such as DAPDC, could resensi-ODC inhibitors, such as difluromethyl ornithine, have
proved useful in the treatment of trypanosomasis [27]. tize resistant strains of S. aureus to -lactam antibiotics.
Our structure of the Mj-DAPDC/azelaic acid complex
revealed that appropriately positioned fluorine atoms Experimental Procedures
could be accommodated within the active site. Vederas
and coworkers have explored the possibility of using Protein Expression and Purification
Genes encoding DAPDCs from S. aureus, E. coli, and M. jannaschiiDAP analogs for inhibition of DAP decarboxylase [28].
were amplified from bacterial genomic DNA (M. jannaschii primers,A number of substrate analogs have been tested for
5-TAAGGATCCCAAGTCATCATGCAACCAG-3 and 5-GCTGCTAGinhibition against DAP epimerase and DAP dehydroge-
CTTAGGTAATGACACAGTAGAG-3; S. aureus primers, 5-GGCGCT
nase, which are also enzymes contributing to lysine bio- AGCACTGTTAAATATAATCAAAATGGCG-3 and 5-GATGGATCCT
synthesis [29, 30, 31, 32]. TCTACAGTCATCTATAATGC-3; E. coli primers, 5-TATGCTAGCAT
GCCACATTCACTGTTCAG-3 and 5-CGAGGATCCCAGGATTTTAGInhibition of an essential gene product often fails to
Crystal Structure of Diaminopimelate Decarboxylase
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ATGGATTCC-3), cloned, and expressed as N-terminal hexaHis-tag mM stock solution. DAPDC activity was estimated by monitoring
CO2 production (i.e., change in OD at 340 nm, reflecting conversionfusion proteins in E. coli BL21(DE3). The recombinant proteins were
purified to homogeneity with nickel ion affinity and anion exchange of NADH to NAD). DAPDC was incubated with varying concentra-
tions of substrate, and velocities were obtained from rate of con-chromatographies. Following proteolytic removal of the affinity tag
with PreScission protease (cut site, NH2-LGVLFQLP-COOH), the ex- sumption of NADH, as previously reported [41]. Data were plotted
as a Line-Weaverburk plot to obtain Vmax and Km from the y interceptpected molecular masses of the proteins were confirmed by mass
spectrometry. and x intercept, respectively. For measurement of Ki for azelaic
acid, known quantities of azelaic acid were added to the assay and
incubated with varying concentrations of substrate. Residual activityCrystallization
was measured as described above. Data were plotted as a Line-Initial crystallization trials with S. aureus (Sa-DAPDC) and E. coli
Weaverburk plot. The Ki for azelaic acid was calculated from the(Ec-DAPDC) enzymes by hanging drop vapor diffusion were unsuc-
slope of the plot with the following equation: the slope of the inhib-cessful. Similar trials with Mj-DAPDC yielded promising leads from
ited reaction equals (1  [I]/Ki)  (Km/Vmax), where [I] is concentrationvarious PEG 6000 conditions, which were optimized to yield small
of azelaic acid. Equal concentrations of all other substrate analogsrod-shaped crystals in the monoclinic space group P21 (unit cell,
were incubated with substrate and enzyme in assay buffer, anda  70.2 A˚, b  147.1 A˚, c  89.4 A˚, and   93.3; four molecules
residual activity was measured and converted to enzyme velocity,per asymmetric unit). Optimization of the monoclinic crystal form
as described above. Apparent Ki values for the remaining substraterequired the addition of the product L-lysine. The final crystallization
analogs were measured relative to that of azelaic acid, which wascondition was 12% (w/v) PEG 6000, 0.1 M Tris-Cl (pH 8.0), 20 mM
used in the same concentration as other inhibitors. Control assaysMgCl2, and 10 mM L-lysine.
were carried out with the coupling enzymes in sodium bicarbonateAddition of a substrate analog, azelaic acid (25 mM), replacing
buffer in the presence of overwhelming concentrations of the inhibi-L-lysine in the monoclinic crystallization condition (Figure 1B), pro-
tors. No loss of activity of the coupling enzymes was observed underduced diffraction-quality crystals in the hexagonal space group
these conditions, indicating that the compounds used for DAPDCP6122 (unit cell, a  80.8 A˚ and c  508.5 A˚; two molecules per
inhibition studies do not crossreact with the coupling enzymes.asymmetric unit). The SeMet form of Mj-DAPDC did not yield crystals
under a wide variety of conditions, requiring a heavy metal soak to
produce an isomorphous derivative of the hexagonal crystal form Acknowledgments
(5 mM dichloro-tetrapyridyl platinum chloride, 6 hr).
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